Tag Archives: pfe

Pfizer, Merck Beat Q2 Views; Sanofi Makes PD-1 Deal

Big pharmas Pfizer (PFE) and Merck (MRK) both beat Q2 estimates and raised guidance Tuesday, while Merck and French counterpart Sanofi (SNY) entered into separate deals to develop immunotherapy drugs for cancer. Pfizer’s earnings dipped 3% to 56 cents a share, but topped analysts’ consensus by 4 cents, according to Thomson Reuters. Sales declined 7% to $11.85 billion, more than $400 million ahead of the Street’s number. Pfizer now sees full-year

Roche ‘High Efficacy’ MS Drug Succeeds In Trials

Genentech, the U.S. biotech arm of Swiss pharma giant Roche (RHHBY), announced Tuesday that its drug candidate ocrelizumab had succeeded in cutting the relapse rate for multiple-sclerosis patients in two late-stage trials. The goal of the studies was to show ocrelizumab is significantly superior to Rebif, a form of interferon sold by Pfizer (PFE). Genentech said it had succeeded in this, and also reduced the lesions in the brain associated with

4 Drug Giants Reporting Earnings This Week

Some of the biggest drugmakers in the world are reporting earnings this week, and while their quarters are expected to be dampened by patent losses and foreign-exchange headwinds, each has a potential growth story in the works. On Tuesday, a trio of big U.S. pharmas are due to report. Pfizer (PFE) is expected to report a 14% drop from year-earlier earnings to 49 cents a share, according to Thomson Reuters’ poll of analysts. Sales are seen falling